The Immunoassays Market – Worldwide Growth, Trends and Forecasts (2019-2024) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Immunoassays
Market – Growth, Trends, and Forecast (2019 – 2024)” report has
been added to ResearchAndMarkets.com’s offering.

The immunoassays market is expected to register a CAGR of 9.7%, over the
forecast period.

Factors that are responsible for the growth of this market include
cost-effectiveness, growth in the biotechnology and pharmaceutical
sectors, and high sensitivity and specificity of immunoassays.

Compared to conventional tests, immunoassays have been proven to provide
highly accurate results even with very small samples. These immunoassays
are considered to have a detection limit of 1pg/ml, which can be
attributed to the fact that immunoassays are based entirely on
immunologic reactions. Immunologic reactions are highly specific, as
they can take place only in the presence of proper immunologic agents.

For instance, an antibody against a viral protein cannot bind with an
antigen that is derived from bacteria. This high specificity indicates
high accuracy in results, which enable high sensitivity in the detection
of diseases. This high sensitivity not only helps in easy detection, but
also eliminates the need for secondary verifications, which ultimately
saves a lot of costs. Thus, the high sensitivity, specificity, and
cost-saving nature of immunoassays are driving the growth of the
immunoassays market. However, factors, such as complex assay procedures
and limitations associated with immunoassays, may hinder the market
growth.

Infectious Disease Segment, under Application, is Expected
to Lead the Market

Immunoassays for infectious disease are expected to lead the market, and
continue the same during the forecast period. This can be mainly
attributed to the upsurge in the prevalence of infectious diseases, such
as Lyme disease, salmonella infections, tuberculosis (TB), and
meningococcal ailments cases.

For instance, according to the Centers for Disease Control and
Prevention (CDC), one-fourth of the world’s population is infected with
TB. In 2017, there were approximately 10 million people, around the
world, who were infected with TB, and 1.3 million deaths occurred due to
TB, across the world. Therefore, utilization of immunoassays may help in
detecting these diseases, which is anticipated to increase the market
growth.

North America Dominates the Market and is Expected to do the
Same during the Forecast Period

Currently, North America dominates the market for immunoassays, and is
expected to continue its stronghold for a few more years. In the North
American region, the United States holds the largest market share. This
can be majorly attributed to the increasing incidence rates of chronic
disorders, infectious diseases, increasing number of geriatric
population, as well as due to the well-developed healthcare
infrastructure and increasing penetration of medical devices in the
region.

Moreover, high expenditure on R&D by government organizations and
pharmaceutical companies, for disorders and diseases, such as chronic
ailments and diabetes, are some of the primary factors driving the
regional market.

Competitive Landscape

The immunoassays market is moderately competitive and consists of
several major players. In terms of the market share, few of the major
players currently dominate the market. With rising need for healthcare
development and the advances in immunoassays, few other smaller players
are expected to enter the market.

Some of the major players of the market are Abbott Laboratories Inc.,
Becton Dickinson and Company, Danaher Corporation, Hologic Inc., and
Qiagen NV, among others.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 High Sensitivity and Specificity of Immunoassays

4.2.2 Cost Effectiveness

4.2.3 Growth in the Biotechnology and Pharmaceutical Sectors

4.3 Market Restraints

4.3.1 Complex Assay Procedures

4.3.2 Limitations Associated with Immunoassays

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Technology

5.1.1 Enzyme Immunoassay

5.1.2 Fluorescence Immunoassay

5.1.3 Chemiluminescence Immunoassay

5.1.4 Radioimmunoassay

5.1.5 Nephelometric Immunoassay

5.1.6 Other Technologies

5.2 By Therapeutic Area

5.2.1 Cardiology

5.2.2 Thyroid

5.2.3 Autoimmune Disease

5.2.4 Oncology

5.2.5 Infectious Disease

5.2.6 Hematology

5.2.7 Allergy

5.2.8 Other Therapeutic Areas

5.3 By End User

5.3.1 Hospital and Centralized Laboratories

5.3.2 Pharma and Biotech Firm

5.3.3 Other End Users

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia-Pacific

5.4.4 Middle East & Africa

5.4.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Abbott Laboratories Inc.

6.1.2 Becton Dickinson and Company

6.1.3 Danaher Corporation

6.1.4 Devon Medical Products

6.1.5 EDP Biotech Corporation

6.1.6 Hologic Inc.

6.1.7 Luminex Corporation

6.1.8 Meridian Life Science Inc.

6.1.9 Qiagen N.V.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/5jq6wq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: In
Vitro Diagnostics